Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy (which was followed by high-dose therapy and autologous stem-cell transplantation in pati...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 386; no. 7; pp. 640 - 654
Main Authors Locke, Frederick L, Miklos, David B, Jacobson, Caron A, Perales, Miguel-Angel, Kersten, Marie-José, Oluwole, Olalekan O, Ghobadi, Armin, Rapoport, Aaron P, McGuirk, Joseph, Pagel, John M, Muñoz, Javier, Farooq, Umar, van Meerten, Tom, Reagan, Patrick M, Sureda, Anna, Flinn, Ian W, Vandenberghe, Peter, Song, Kevin W, Dickinson, Michael, Minnema, Monique C, Riedell, Peter A, Leslie, Lori A, Chaganti, Sridhar, Yang, Yin, Filosto, Simone, Shah, Jina, Schupp, Marco, To, Christina, Cheng, Paul, Gordon, Leo I, Westin, Jason R
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 17.02.2022
Subjects
Adult
Age
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Autografts
B-cell lymphoma
Biological Products - adverse effects
Biological Products - therapeutic use
Bone marrow
Bone Marrow Transplantation
CD19 antigen
Cell therapy
Chemotherapy
Chimeric antigen receptors
Cytokines
Drug Resistance, Neoplasm
Female
Genetics
Genetics General
Hematology
Humans
Immunotherapy
Immunotherapy, Adoptive
Leukemia
Lymphocytes B
Lymphocytes T
Lymphoma
Lymphoma, Large B-Cell, Diffuse - drug therapy
Male
Medical prognosis
Middle Aged
Oncology
Progression-Free Survival
Receptors, Chimeric Antigen - antagonists & inhibitors
Statistical analysis
Stem Cell Transplantation
Transplantation, Autologous
Treatments in Oncology
Online AccessGet full text

Cover

More Information
Summary:In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy (which was followed by high-dose therapy and autologous stem-cell transplantation in patients with a response). High-grade toxic effects were common, but most patients recovered.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2116133